KLRK1 and prostate cancer: Clayton et al. [12], [13] showed that exosomes released by breast-, mesotelioma and prostate cancer cell lines expressed NKG2D ligands with ability to down modulate the cognate NK cell receptor and impair the cytotoxic anti-cancer immune response.